688076 Stock Overview
A biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥54.68 |
| 52 Week High | CN¥81.50 |
| 52 Week Low | CN¥35.63 |
| Beta | 0.56 |
| 11 Month Change | 1.56% |
| 3 Month Change | -3.90% |
| 1 Year Change | 27.76% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 67.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688076 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.0% | -1.4% | -2.0% |
| 1Y | 27.8% | -6.0% | 4.6% |
Return vs Industry: 688076 exceeded the CN Pharmaceuticals industry which returned -8.7% over the past year.
Return vs Market: 688076 exceeded the CN Market which returned 2% over the past year.
Price Volatility
| 688076 volatility | |
|---|---|
| 688076 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688076 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688076's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,779 | n/a | www.sinopep.com.cn |
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates.
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Fundamentals Summary
| 688076 fundamental statistics | |
|---|---|
| Market cap | CN¥12.02b |
| Earnings (TTM) | CN¥421.47m |
| Revenue (TTM) | CN¥1.58b |
28.5x
P/E Ratio7.6x
P/S RatioIs 688076 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688076 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.58b |
| Cost of Revenue | CN¥549.57m |
| Gross Profit | CN¥1.03b |
| Other Expenses | CN¥605.29m |
| Earnings | CN¥421.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 65.14% |
| Net Profit Margin | 26.74% |
| Debt/Equity Ratio | 49.4% |
How did 688076 perform over the long term?
See historical performance and comparison